Clicky

Stoke Therapeutics, Inc.(STOK)

Description: Stoke Therapeutics is a biotechnology company that is pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression to restore target proteins to near normal levels. Stoke aims to develop the first precision medicine platform to target the underlying cause of a broad spectrum of genetic diseases in which the patient has one healthy copy of a gene and one mutated copy that fails to produce a protein essential to health. These diseases, in which loss of approximately 50 percent of normal protein expression causes disease, are called autosomal dominant haploinsufficiencies. Stoke was launched with investments by Apple Tree Partners. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts.


Keywords: Biotechnology Disease Proteins Precision Medicine Genetic Diseases Epigenetics Severe Genetic Diseases

Home Page: www.stoketherapeutics.com

STOK Technical Analysis

45 Wiggins Avenue
Bedford, MA 01730
United States
Phone: 781 430 8200


Officers

Name Title
Dr. Edward M. Kaye M.D., Ph.D. CEO & Director
Dr. Adrian R. Krainer Ph.D. Co-Founder, Independent Director & Member of Scientific Advisory Board
Mr. Stephen J. Tulipano CPA, CPA, MBA Chief Financial Officer
Dr. Barry S. Ticho FACC, M.D., Ph.D. Chief Medical Officer
Ms. Isabel Aznarez Ph.D. Co-Founder & Group VP of Discovery Research
Dr. Huw M. Nash Ph.D. COO & Chief Bus. Officer
Mr. Eric Rojas Head of Investor Relations
Mr. Jonathan Allan J.D. Gen. Counsel
Ms. Dawn Kalmar Chief Communications Officer
Ms. Joan Wood Chief HR Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

GIC Sector: Health Care
GIC Group: Pharmaceuticals, Biotechnology & Life Sciences
GIC Industry: Biotechnology
GIC Sub-Industry:
Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.6186
Price-to-Sales TTM: 35.8186
IPO Date: 2019-06-19
Fiscal Year End: December
Full Time Employees: 102
Back to stocks